-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CDK4/6 inhibitors (CDK4/6i) can prevent the transition of the cell cycle from G1 to S phase and show promise in overcoming endocrine resistance
Breast cancer
CDK4/6 inhibitors can regulate the immune response of breast cancer
Immunization Eur J Cancer Eur J Cancer
Patients with stage IV HR+HER2-metastatic breast cancer were recruited and treated with pabocinil, pembrolizumab, and letrozole
From November 2016 to July 2020, a total of 23 patients were recruited, of which 20 were available for reactivity assessment, of which 4 were in cohort 1 and 16 were in cohort 2
Grade 3-4 adverse reactions are neutropenia (83%), leukopenia (65%), thrombocytopenia (17%) and elevated liver enzymes (17%)
Grade 3-4 adverse reactions are neutropenia (83%), leukopenia (65%), thrombocytopenia (17%) and elevated liver enzymes (17%)
PFS and OS in 2 cohorts
PFS and OS in 2 cohortsIn cohort 1, 50% of patients achieved partial remission (PR), and 50% of patients had stable disease (SD)
In the 2 cohorts, 31% of patients achieved complete remission (CR), 25% of patients achieved PR, and 31% of patients achieved SD
In summary, the combination of Pabocinib , pembrolizumab, and letrozole is well tolerated in patients with HR+ metastatic breast cancer, and the complete remission rate can be as high as 31%
The combined regimen of Pabocinil, Pembrolizumab and Letrozole is well tolerated in patients with HR+ metastatic breast cancer, and the complete remission rate can be as high as 31%.
Original source:
Yuan Yuan,Lee Jin Sun,Yost Susan E et al.
Phase I / II trial of palbociclib, pembrolizumab? And letrozole in patients with hormone receptor-positive metastatic breast cancer
in this message
